<DOC>
	<DOCNO>NCT01238978</DOCNO>
	<brief_summary>The study assess incidence Hypoglycemia : Percent patient present hypoglycemia ( confirmed event SMBG severe episodes ) 6 month follow T2DM patient treat DPP-4 inhibitor another OAD add-on therapy metformin</brief_summary>
	<brief_title>Phase 4 Study Elderly Patients With T2DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus ( DM ) patient age 65 80 year , willing perform SMBG case symptomatic hypoglycemia . HbA1c : 6.5 8.5 % max tolerate dose metformin monotherapy least 3 month . Age &gt; 80 yr BMI &lt; 22 â‰¥ 45 kg/m2 Secondary T2 DM Hepatic failure , moderate/severe renal failure ( Cl &lt; 50 ml/min ) CHF III &amp; IV ASAT / ALAT &gt; 3 ULN , creatinine clearance &lt; 50 ml/min Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes mellitus , vildagliptin , hypoglycemia , elderly</keyword>
</DOC>